GYRE has been in the news 324% more than usual
Apr 29, 2025, 2:32 PM
-7.94%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: GYRE THERAPEUTICS is not directly mentioned in the provided information, but several biotech companies are advancing cancer treatment and drug delivery technologies. Notable developments include Nona Biosciences' announcement of Pfizer's promising preclinical data on a cancer antibody-drug conjugate and Kineta's KVA12123 trial demonstrating significant receptor occupancy in cancer treatment.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
